Quantcast

PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating


Shutterstock photo

The Relative Strength ( RS ) Rating for PTC Therapeutics ( PTCT ) entered a new percentile Tuesday, with a rise from 79 to 82.

[ibd-display-video id=2385970 width=50 float=left autostart=true] This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against the rest of the market.

Over 100 years of market history shows that the top-performing stocks typically have an 80 or higher RS Rating as they launch their biggest price moves.

See How IBD Helps You Make More Money In Stocks

PTC Therapeutics is building a consolidation with a 22.10 buy point . See if it can break out in heavy trade.

Earnings growth rose last quarter from 0% to 20%. But revenue gains fell from 207% to 82%.

PTC Therapeutics earns the No. 93 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Vertex Pharmaceuticals ( VRTX ) and Sucampo Pharmaceuticals ( SCMP ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: RS , PTCT , CORT , VRTX ,



More from Investor's Business Daily

Subscribe






Investor's Business Daily
Contributor:

Investor's Business Daily

Investing










Research Brokers before you trade

Want to trade FX?